SLC5A2 and chronic kidney disease: The DAPA-CKD trial, the first renal outcome study of SGLT2 inhibitors in CKD patients (with or without type 2 diabetes), demonstrated that dapagliflozin significantly reduced: Primary composite endpoint risk (eGFR decline ≥ 50%, progression to ESRD, renal/cardiovascular death) by 39%.